Back to search results

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Ovarian Cancer · Endometrial Cancer · Germ Cell Tumor · Testicular Germ Cell Tumor · Ovarian Germ Cell Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope, Duarte, California, United States

  • Stanford, Palo Alto, California, United States

  • University of California, San Francisco, California, United States

  • Moffitt Cancer Center, Tampa, Florida, United States

  • Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

  • University of Chicago Medical Center, Chicago, Illinois, United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

  • Karmanos Cancer Institute, Detroit, Michigan, United States

  • University of Minnesota, Minneapolis, Minnesota, United States

  • The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Montefiore Einstein Comprehensive Cancer Center, The Bronx, New York, United States

  • The Ohio State University, Columbus, Ohio, United States

  • OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

  • SCRI Oncology Partners, Nashville, Tennessee, United States

  • University of Virginia, Charlottesville, Virginia, United States

  • Herlev Gentofte Hospital, Herlev, Denmark

View source on ClinicalTrials.gov(opens in a new tab)